Sustained tip shock
Specialty: Cardiovascular.
Why it occurs
- Severe concentric left ventricular hypertrophy (secondary to aortic stenosis or chronic hypertensive heart disease)
- Hypertrophic cardiomyopathy
- Chronic aortic or mitral valve regurgitation with massive left ventricular overload
- Severe aortic coarctation
- Long-term severe uncontrolled systemic arterial hypertension
Initial workup
12-lead electrocardiogram to quantify the degree of left ventricular hypertrophy using the Sokolow-Lyon index (S wave in V1 + R wave in V5 or V6 >35 mm) or the Cornell index, and assess the presence of asymmetric inverted T waves with a systolic overload pattern; Two-dimensional transthoracic echocardiogram with Doppler to accurately measure the thickness of the interventricular septum and the posterior wall (hypertrophy if thickness >=12 mm), estimate the indexed mass of the left ventricle, evaluate systolic and diastolic function, and rule out obstruction in the ventricular outflow tract; Chest x-ray.
red flags
Toe shock that is palpable as an energetic, wide rise that persists throughout systole, occupying more than half of it in the precordial examination (unlike the normal hyperdynamic beat which is brief), associated with syncope or presyncope on exertion, oppressive anginal substernal pain triggered by physical exercise, dyspnea on minimal effort, audible fourth heart sound (R4 gallop auricular), or severely elevated blood pressure levels (BP >180/120 mmHg with headache or scotomas). It suggests massive left ventricular hypertrophy with a high risk of functional myocardial ischemia, lethal ventricular arrhythmias, or sudden cardiovascular death.
Standard management
- Metoprolol succinate — beta blocker indicated to reduce heart rate, reduce myocardial oxygen consumption and attenuate pathological hypertrophy; 25 to 100 mg once daily orally, titrating to clinical tolerance and target heart rate
- Losartan — ARA-II indicated in hypertensive heart disease to promote the regression of ventricular hypertrophy and control blood pressure levels; 50 to 100 mg once daily orally
- Verapamil — non-dihydropyridine calcium antagonist indicated as an alternative if beta-blockers are contraindicated or in hypertrophic cardiomyopathy; 120 to 240 mg daily in divided doses, monitoring atrioventricular conduction
- Ramipril (ACEI to control hypertension and reduce afterload; 5 to 10 mg per day orally).
Educational guidance for study. It is NOT a prescription recommendation. The actual choice depends on the cause, the patient, and current guidelines.
- Area
- Cardiovascular
- Listed causes
- 5
- Treatment options
- 4